Navigation Links
Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
Date:10/11/2007

PARIS, October 11 /PRNewswire-FirstCall/ --

(EUR millions) 2007 2006 07/06

%Sales %Sales %

change

Southern Europe (1) 20.63 70.6 17.61 70.7 17

Other EU countries (2) 7.07 24.2 6.06 24.4 17

Other markets 1.51 5.2 1.22 4.9 24

SLIT 22.13 75.8 18.14 72.9 22

SCIT 5.96 20.4 5.60 22.5 6

Other products 1.12 3.8 1.15 4.6 (3)

Total Q3 sales 29.21 100.0 24.89 100.0 17

Southern Europe (1) 77.16 74.2 65.71 73.8 17

Other EU countries (2) 22.83 21.9 19.78 22.2 15

Other markets 4.02 3.9 3.60 4.0 12

SLIT 81.88 78.7 67.55 75.8 21

SCIT 17.78 17.1 17.23 19.3 3

Other products 4.35 4.2 4.31 4.8 1

9-month cumulated sales 104.01 100.0 89.09 100.0 17

(1) Portugal, Spain, France, Italy, Greece;

(2) Switzerland included

Sales growth and financial position

2007 3rd quarter sales registered further significant growth in all markets (+17%, vs +9% in 2006). The most vigorous market segment remained sublingual route desensitization (SLIT, +22%). Subcutaneous route sales (SCIT) increased by 6%. Cumulative sales for the first nine months of the year increased by 17% (vs +13% in 2006).

The financial position improved. Net debt declined 40% from net debt at 30 September 2006.

Significant 3rd quarter transactions and events

The new allergen production facility has been completed. Collection a
'/>"/>

SOURCE Stallergenes
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Midwest life science stocks sizzle in a tepid first quarter
2. CIOs looking to hire more IT workers in second quarter
3. Fiserv posts 30 percent quarterly loss
4. Sonic Foundry reports first cash-positive quarter
5. Venture capital above $6B for third straight quarter
6. Third Wave reports $5.2M third quarter loss
7. Inventions could fall prey to Monday morning quarterbacking
8. Merge fails to file quarterly financial report
9. Rexnord to slash debt after quarterly loss
10. Johnson Controls reports record quarterly sales
11. Sonic Foundry reports quarterly loss, higher Mediasite sales
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4Scientists discover gene module underlying atherosclerosis development 2How to read brain activity? 2Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 1Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 2Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 3Help Save a Life Bone Marrow Donor Registry Drive Sept 2 at the Karmanos Cancer Center 55320 4Nuvilex to Issue Positive Shareholder Newsletter 55318 1Nuvilex to Issue Positive Shareholder Newsletter 55318 2Nuvilex to Issue Positive Shareholder Newsletter 55318 3Nuvilex to Issue Positive Shareholder Newsletter 55318 4Nuvilex to Issue Positive Shareholder Newsletter 55318 5NexBio 28R 29 Demonstrates DAS181 28Fludase 28R 29 29 a Broad Spectrum Drug Candidate Inhibits Influenza Viral Infection in Human Lung Tissue 13689 1NexBio 28R 29 Demonstrates DAS181 28Fludase 28R 29 29 a Broad Spectrum Drug Candidate Inhibits Influenza Viral Infection in Human Lung Tissue 13689 2NexBio 28R 29 Demonstrates DAS181 28Fludase 28R 29 29 a Broad Spectrum Drug Candidate Inhibits Influenza Viral Infection in Human Lung Tissue 13689 3NexBio 28R 29 Demonstrates DAS181 28Fludase 28R 29 29 a Broad Spectrum Drug Candidate Inhibits Influenza Viral Infection in Human Lung Tissue 13689 4